Mohamed Helal
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,081 and has fallen 97.7% since, to $25 in 2025. That places this record below the midpoint for urology clinicians in FL, where the typical reported total is $3,881.
Across 150 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$385
- Dendreon Pharmaceuticals LLC$354
- AbbVie$259
- Endo Pharmaceuticals Inc.$217
- Astellas Pharma US Inc$188
- Bayer$165
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,87499%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 23 | $385 |
| Dendreon Pharmaceuticals LLC | 15 | $354 |
| AbbVie(2 entities) | 15 | $259 |
| Endo Pharmaceuticals Inc. | 10 | $217 |
| Astellas Pharma US Inc | 10 | $188 |
| Bayer | 10 | $165 |
| Axonics, Inc. | 6 | $138 |
| Travere Therapeutics, Inc. | 7 | $127 |
| Tolmar Pharmaceuticals, Inc. | 6 | $119 |
| Urovant Sciences Inc | 4 | $84 |
| Pfizer | 4 | $68 |
| Blue Earth Diagnostics | 2 | $65 |
| Clarus Therapeutics Inc. | 3 | $65 |
| Myovant Sciences Inc. | 3 | $55 |
| Neotract Inc. | 2 | $52 |
| Urogen Pharma, Inc. | 3 | $50 |
| Sun Pharmaceutical Industries Inc. | 2 | $46 |
| Metuchen Pharmaceuticals | 2 | $39 |
| Amgen | 2 | $38 |
| AstraZeneca | 2 | $37 |
| Boston Scientific | 1 | $37 |
| Antares Pharma, Inc. | 2 | $37 |
| Myriad Genetic Laboratories, Inc. | 2 | $34 |
| Merck | 2 | $33 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $30 |
| Foundation Medicine, Inc. | 1 | $29 |
| Medtronic(2 entities) | 2 | $28 |
| Telix Pharmaceuticals | 1 | $23 |
| Laborie Medical Technologies Corp. | 1 | $22 |
| EDAP Technomed Inc | 1 | $17 |
| Ambu Inc. | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Mission Pharmacal Company | 1 | $15 |
| Teleflex LLC | 1 | $12 |
How this compares
$2,900 in reported general payments places this provider in the 40th percentile of 935 urology providers in Florida.
Other urology in Tampa
- Rafael CarrionTampa$240K
- Raviender BukkapatnamTampa$115K
- Trushar PatelTampa$88K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.